GlassScriptPhysician profile
Lauren A Rome
NPI 1972544823
$10,441.40
in general payments reported to CMS, 2019-2025
43 companies · $1,765 in 2025
The $1,765 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,461 · 2020: $1,256 · 2021: $1,603 · 2022: $1,349 · 2023: $1,146 · 2024: $863 · 2025: $1,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,588 · Consulting Fee: $150 · Education: $35.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,587.72 |
| Consulting Fee | $150.00 |
| Education | $35.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,713.41 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,166.11 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,055.79 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Janssen Pharmaceuticals, INC | $812.42 | 2019-2023 | Xarelto |
| Mylan Specialty L.P. | $726.67 | 2019-2024 | Yupelri |
| Philips North America LLC | $574.01 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $508.51 | 2019-2024 | Dupixent |
| Insmed, INC. | $377.67 | 2019-2025 | Arikayce |
| Viatris Specialty LLC | $271.06 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $259.90 | 2019-2025 | Xywav |
| Genzyme Corporation | $204.34 | 2019-2025 | |
| Genentech USA, INC. | $172.32 | 2019-2025 | Xolair |
| Amgen INC. | $146.50 | 2022-2025 | Tezspire |
| Zoll Respicardia, INC. | $131.74 | 2019 | |
| Electromed, INC. | $117.78 | 2019-2024 | Smartvest |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Rome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.